| ADTX 0.0127 -2.31% | SOXS 4.72 -5.03% | SPCX 160.95 19.22% | DFNS 0.233 -9.20% | BITO 8.65 0.12% | RUBI 0.4676 -24.62% | TZA 4.16 -2.58% | CAST 1.55 140.68% | AAL 14.98 2.25% | INTC 124.57 6.51% | SPCE 3.91 -31.76% | SHFS 0.276 16.46% | SRXH 0.148 17.65% | NOK 14.795 5.00% | NVDA 205.19 0.16% | BYAH 1.47 40.00% | SPDN 8.81 -0.45% | TQQQ 77.52 1.99% | TSLL 13.59 3.58% | PAVS 0.208 -28.28% | CPOP 0.195 -81.43% | SMCI 30.46 -4.72% | CUPR 3.97 64.73% | VSME 1.69 52.25% | YYGH 0.119 -3.25% | SQQQ 40.04 -1.93% | RKLB 102.39 -10.79% | TSLA 406.43 1.82% | NVD 5.02 -0.40% | WOK 0.0753 -17.70% | SPY 741.75 0.54% | ASTS 82.41 -15.53% | KEEL 5.59 1.27% | ONDS 9.33 -5.09% | SPYM 87.06 0.25% | AMZN 238.55 -1.23% | XLF 53.34 1.37% | SATS 114.08 -10.97% | QQQ 721.34 0.59% | SOFI 16.58 -0.54% | PLUG 2.76 -2.47% | SOXL 234.68 4.77% | GRAB 3.3 -1.49% | DRIP 4.74 -2.47% | AMC 2.34 2.63% | IREN 59.77 5.40% | HKIT 0.5025 -10.11% | RKLZ 3.01 21.37% | RZLV 2.68 5.93% | MARA 14.08 3.45%

HealthEquity, Inc. (NASDAQ: HQY) Maintains Strong Financial Performance

HealthEquity, Inc. (NASDAQ: HQY) is a prominent player in the medical services industry, specializing in health savings accounts (HSAs) and related financial services. The company is known for its strong financial performance and strategic initiatives aimed at enhancing member savings, spending, and investment strategies. HealthEquity competes with other financial service providers in the healthcare sector, striving to maintain its market position through consistent growth and innovation.

On December 4, 2025, Citigroup maintained its "Outperform" rating for HQY, with the stock priced at $98.64. This rating reflects confidence in HealthEquity's ability to deliver strong financial results and maintain its competitive edge. Citizens JMP also raised the price target for HQY from $117 to $122, as highlighted by TheFly, indicating positive expectations for the company's future performance.

HealthEquity's recent Q3 2026 earnings call, as reported by Seeking Alpha, showcased the company's impressive financial results. The company reported earnings of $1.01 per share, surpassing the Zacks Consensus Estimate of $0.90 per share. This represents a 12.22% earnings surprise and a significant increase from the $0.78 per share reported in the same quarter last year. HealthEquity has consistently exceeded consensus EPS estimates in three of the past four quarters.

In terms of revenue, HealthEquity generated $322.16 million for the quarter ending October 2025, exceeding the Zacks Consensus Estimate by 0.69%. This marks a 7% increase from the $300.43 million reported in the same period last year. The company's strong revenue growth is a testament to its ability to capitalize on market opportunities and deliver value to its stakeholders.

HealthEquity's strategic initiatives have also contributed to its financial success. The company returned $93.7 million to shareholders through stock repurchases and implemented a $2.25 billion 5-year Treasury bond hedge to mitigate HSA cash repricing risk. With total HSA assets growing by 15% to $34.4 billion, HealthEquity continues to demonstrate its commitment to enhancing member savings and investment strategies.

Published on: December 4, 2025